Status:
RECRUITING
Growth Evaluation, Health Promotion, and Clinical Management in Children and Adolescents With Thalassemia
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Conditions:
Thalassemia Intermedia
Thalassemia Major
Eligibility:
All Genders
Up to 18 years
Phase:
NA
Brief Summary
There are nearly 300,000 patients with severe or intermediate thalassemia in China. Growth retardation is the most significant health issue for children and adolescents with transfusion-dependent thal...
Eligibility Criteria
Inclusion
- Subjects diagnosed with transfusion-dependent thalassemia (TDT)
- Male or female age ≤18 years
- Subjects who are willing and able to provide written informed consent
Exclusion
- Not applicable
Key Trial Info
Start Date :
December 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 30 2026
Estimated Enrollment :
369 Patients enrolled
Trial Details
Trial ID
NCT06931912
Start Date
December 1 2024
End Date
November 30 2026
Last Update
April 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Regenerative Medicine Center and Red Blood Cell Disorders Center
Tianjin, Tianjin Municipality, China